Portal de recerca
VALORACIÓN DE LA TOLERABILIDAD DE UN COMPLEMENTO ALIMENTICIO DE HIERRO LIPOSOMADO ORAL (FISIOGEN FERRO FORTE®) EN EL DÉFICIT DE HIERRO EN PACIENTES CON ENFERMEDAD INFLAMATORIA INTESTINAL.
Dades bàsiques
- Protocol:
- FIFERM02
- EURDRACT:
- NCT:
- Centre:
- Any inici:
- Any de finalització:
Documents
- No hi ha documents
Participants
Grups d'Investigació
Finançadors - Promotors
Resultats de l'Assaig Clínic
A genome-wide association study identifies a novel locus at 6q22.1 associated with ulcerative colitis
Julià A; (...); Marsal S
Article. 10.1093/hmg/ddu398. 2014
A genome-wide association study identifies DSE-FAM26F as a risk locus for ulcerative colitis
Domenech, E.; (...); Gisbert, J. P.
Article. 10.1016/S1873-9946(14)60784-4. 2014
A genome-wide association study on a southern European population identifies a new Crohn's disease susceptibility locus at RBX1-EP300.
Julià A; (...); Marsal S
Article. 10.1136/gutjnl-2012-302865. 2013
A Nomogram Combining Fecal Calprotectin Levels and Plasma Cytokine Profiles for Individual Prediction of Postoperative Crohn's Disease Recurrence.
Cerrillo E; (...); Beltrán B
Article. 10.1093/ibd/izz053. 2019
A telemanagement system web in patients with complex inflammatory bowel disease: design and implementation of a randomized clinical trial
Meeting Abstract. 2017
A Web-Based Telemanagement System for Improving Disease Activity and Quality of Life in Patients With Complex Inflammatory Bowel Disease: Pilot Randomized Controlled Trial
Del Hoyo, Javier; (...); Aguas, Mariam
Article. 10.2196/11602. 2018
A web-based telemanagement system for patients with complex Inflammatory Bowel Disease (TECCU): Results of a randomised controlled clinical trial
Meeting Abstract. 2018
A Web-Based Telemanagement System for Patients With Complex Inflammatory Bowel Disease: Protocol for a Randomized Controlled Clinical Trial
Aguas, Mariam; (...); Nos, Pilar
Article. 10.2196/resprot.9639. 2018
Accuracy of magnetic resonance enterography in the preoperative assessment of patients with Crohn's disease of the small bowel
Pous-Serrano, S; (...); Garcia-Granero, E
Article. 10.1111/codi.13613. 2017
Acute cholecystitis after colonoscopy: A rare complication.
Ladrón Abia P; (...); Del Hoyo F
Article. 10.1016/j.rgmxen.2022.05.007. 2022
Acute cholecystitis after colonoscopy: A rarecomplication
Abia, P. Ladron; (...); Del Hoyo, F.
Letter. 10.1016/j.rgmx.2022.03.003. 2022
Adalimumab or Infliximab for the Prevention of Early Postoperative Recurrence of Crohn Disease: Results From the ENEIDA Registry.
Cañete F; (...); ENEIDA registry by GETECCU
Article. 10.1093/ibd/izz084. 2019
Adalimumab vs Azathioprine in the Prevention of Postoperative Crohn's Disease Recurrence. A GETECCU Randomised Trial
Lopez-Sanroman, A; (...); Spanish GETECCU Grp APPRECIA Study
Article. 10.1093/ecco-jcc/jjx051. 2017
Adaptation of TECCU App Based on Patients ' Perceptions for the Telemonitoring of Inflammatory Bowel Disease: A Qualitative Study Using Focus Groups
Del Hoyo, J; (...); Aguas, M
Article. 10.3390/ijerph17061871. 2020
Adaptation of TECCU App based on patients' perceptions for telemonitoring inflammatory bowel disease: A qualitative study using focus groups
Francisco, JD; (...); Aguas, M
Meeting Abstract. 2020
Adherence to diagnostic and treatment recommendations for the management of acute severe ulcerative colitis: a prospective and multinational study
Rodriguez-Lago, I.; (...); Gisbert, J. P.
Meeting Abstract. 2024
Adsorptive granulocyte/monocyte apheresis use in severe ulcerative colitis and determination of changes in plasma cytokines
Beltran, B; (...); Nos, P
Article. 10.1002/jca.21552. 2018
Advanced endoscopy technologies to improve the detection and characterisation of colorrectal polyps.
Sánchez-Montes C; (...); Fernández-Esparrach G
Review. 10.1016/j.gastrohep.2019.09.008. 2020
Alpha-defensins (alpha-Defs) in Crohn's disease: decrease of ileal alpha-Def 5 via permanent methylation and increase in plasma alpha-Def 1-3 concentrations offering biomarker utility
Cerrillo, E; (...); Beltran, B
Article. 10.1111/cei.13085. 2018
Analysis of intestinal tissue from newly diagnosed patients with inflammatory bowel disease reveals distinct proteomic profiles
Baldan-Martin, M.; (...); Chaparro, M.
Meeting Abstract. 2023
Anti-TNFs patterns of use in clinical practice in inflammatory bowel disease (VERNE study)
Bastida, G; (...); Barreiro-de Acosta, M
Meeting Abstract. 10.1093/ecco-jcc/jjy222.251. 2019
Antitumor Necrosis Factor Agents to Treat Endoscopic Postoperative Recurrence of Crohn's Disease: A Nationwide Study With Propensity-Matched Score Analysis
Canete, F; (...); Domenech, E
Article. 10.14309/ctg.0000000000000218. 2020
Anti-tumour necrosis factor discontinuation in inflammatory bowel disease patients in remission: study protocol of a prospective, multicentre, randomized clinical trial
Chaparro, M; (...); EXIT Study Grp GETECCU
Article. 10.1177/1756284819874202. 2019
Are we ready for telemonitoring inflammatory bowel disease? A review of advances, enablers, and barriers.
Del Hoyo, Javier; (...); Aguas, Mariam
Article. 10.3748/wjg.v29.i7.1139. 2023
Association between Chronotype, Physical Activity and Sedentary Behaviour: A Systematic Review
Sempere-Rubio, Nuria, Aguas, Mariam, Faubel, Raquel
Article. 10.3390/ijerph19159646. 2022
Association between disease activity and quality of life in ulcerative colitis: Results from the CRONICA-UC study
Panes, Julian; (...); Marin-Jimenez, Ignacio
Article. 10.1111/jgh.13795. 2017
Bases for the Adequate Development of Nutritional Recommendations for Patients with Inflammatory Bowel Disease
SÁEZ, E.; (...); BELTRÁN, B.
Article. 10.3390/nu11051062. 2019
Basic training in digestive endoscopy for resident physicians in gastroenterology. Recommendations by the Sociedad Española de Endoscopia Digestiva (SEED).
Brotons Á; (...); Dolz Abadía C
Article. 10.17235/reed.2018.5545/2018. 2019
Catalase inhibition can modulate the ability of peripheral blood T cells to undergo apoptosis in Crohn's disease.
Moret-Tatay, Ines; (...); Beltran, Belen
Article. 10.1093/cei/uxad134. 2024
Certification of integral care IBD Units: Evaluation of a certification program (CUE)
Barreiro-de Acosta, M; (...); GETECCU
Meeting Abstract. 2020
Clinical and treatment outcomes of a second subcutaneous or intravenous anti-TNF in patients with ulcerative colitis treated with two consecutive anti-TNF agents: data from the ENEIDA registry.
Calafat, Margalida; (...); Domenech, Eugeni
Article. 10.1177/17562848231221713. 2024
Clinical Approach to STRIDE-II in Real-Life Settings: Analysis and Practical Recommendations.
Ricart E; (...); González-Lama Y
Article. 10.1093/crocol/otae055. 2024
Clinical characteristics, risk factors and management of patients with inflammatory bowel disease and hidradenitis suppurativa: a nationwide multicenter study of the GETECCU ENEIDA registry
Madero Velazquez, L.; (...); Gutierrez-Casbas, A.
Meeting Abstract. 2024
Clinical outcomes in familial versus sporadic inflammatory bowel disease diagnosed in the era of biological therapies. Prospective data from the ENEIDA registry
Gonzalez Munoza, C.; (...); Garcia-Planella, E.
Meeting Abstract. 2022
Cold loop polypectomy perforation of a tiny colon polyp.
Mínguez Sabater A; (...); Bustamante-Balén M
Article. 10.17235/reed.2021.8221/2021. 2021
Colorectal cancer diagnosis in patients with inflammatory bowel disease in Spain: A room for improvement
Saldana, R; (...); Mateu, PN
Meeting Abstract. 2020
Combination therapy with cytapheresis plus vedolizumab in a corticosteroid-dependent patient with ulcerative colitis and previous ANTI-TNF-alpha drug failure
Saez-Gonzalez, E; (...); Beltran, B
Letter. 10.1016/j.dld.2018.01.124. 2018
Controversies in the management of anti-TNF therapy in Crohn's disease patients. A Delphi consensus
Gonzalez Lama, Y.; (...); Munoz, F.
Meeting Abstract. 2023
Correlation between fecal calprotectin and inflammation in the surgical specimen of Crohn's disease
Pous-Serrano, Salvador; (...); Nos, Pilar
Article. 10.1016/j.jss.2017.02.064. 2017
Corrigendum to “Recomendaciones del Grupo Español de Trabajo en enfermedad de Crohn y colitis ulcerosa (GETECCU) sobre la reservoritis en la colitis ulcerosa. Parte 2: Tratamiento” [Gastroenterología y Hepatología 2020;43(10):649-658].
Barreiro-de Acosta M; (...); Nos P
Correction. 10.1016/j.gastrohep.2021.02.001. 2021
Corrigendum to: Re-induction With Intravenous Ustekinumab in Patients With Crohn's Disease and a Loss of Response to This Therapy.
Bermejo F; (...); Guerra I
Article. 10.1093/ibd/izab242. 2021
Cost of telemonitoring with the App TECCU in Inflammatory Bowel Disease compared to standard care in Spain: a multicenter clinical trial of GETECCU
Aguas Peris, M.; (...); Nos, P.
Meeting Abstract. 10.1093/ecco-jcc/jjae190.0428. 2025
Cost-effectiveness of Telemedicine-directed Specialized vs Standard Care for Patients With Inflammatory Bowel Diseases in a Randomized Trial.
Del Hoyo J, Aguas M
Letter. 10.1016/j.cgh.2020.06.016. 2021
Crohn's disease and self-monitoring through a mobile App: The Medicrohn study
Echarri, A; (...); Nos, P
Meeting Abstract. 2018
Changes in the management of IBD patients since the onset of COVID-19 pandemic. A path toward the implementation of telemedicine in Spain?
Del Hoyo, Javier; (...); Aguas, Mariam
Article. 10.1016/j.gastrohep.2021.08.006. 2021
Changes in the management of IBD patients since the onset of COVID-19 pandemic. A path towards the implementation of telemedicine in Spain?
Del Hoyo Francisco, J.; (...); Aguas, M.
Meeting Abstract. 10.1093/ecco-jcc/jjab076.758. 2021
Changes in the requirement for early surgery in inflammatory bowel disease in the era of biological agents.
Guasch M; (...); Domènech E
Article. 10.1111/jgh.15084. 2020
Characteristics and treatment of pyoderma gangrenosum in inflammatory bowel disease.
Argüelles-Arias F; (...); Herrerías-Gutiérrez JM
Article. 10.1007/s10620-013-2762-2. 2013
Characteristics of drug-induced lupus 2 degrees to anti-TNF agents in inflammatory bowel disease patients and evolution after switch to a second anti-TNF
Manosa, M; (...); Domenech, E
Meeting Abstract. 2017
Characteristics of inflammatory bowel disease in patients of Roma/Gypsy ethnicity. A case-control study
Cabre, E; (...); Domenech, E
Article. 10.1016/j.dld.2018.12.004. 2019
Characteristics of the stricture, not the ongoing treatment, influence the outcome of endoscopic dilatation in recurrent Crohn's disease
Ladron Abia, P.; (...); Iborra, M.
Meeting Abstract. 10.1093/ecco-jcc/jjab076.537. 2021
Delayed diagnosis of inflammatory bowel disease in women: Characterization and use of health resources
Sempere Robles, L.; (...); Ruiz, M. T.
Article. 2022
Depression and anxiety symptoms among patients with early inflammatory bowel disease during and after COVID-19 lockdown
Sempere Robles, L.; (...); van-der Hofstadt, C.
Meeting Abstract. 10.1093/ecco-jcc/jjab076.270. 2021
Diagnosis of non-Hodgkin's lymphoma due to a tiny polyp in the cecum.
Argumánez Tello V; (...); Bustamante-Balén M
Article. 10.17235/reed.2023.9543/2023. 2023
Diagnostic yield of endoscopic ultrasound with fine-needle aspiration in pancreatic cystic lesions.
Argüello L; (...); Pons-Beltrán V
Article. 10.1016/j.gastrohep.2019.07.012. 2020
Different Genetic Expression Profiles of Oxidative Stress and Apoptosis-Related Genes in Crohn's Disease
Iborra, M; (...); Beltran, B
Article. 10.1159/000493726. 2019
Differential cytokine profiles and drop of faecal calprotectin for prediction of primary response to infliximab induction therapy in Crohn's disease
Mateos, B; (...); Beltran, B
Meeting Abstract. 10.1093/ecco-jcc/jjy222.725. 2019
Disease severity in familial cases of IBD
Andreu M; (...); Panés J
Article. 10.1016/j.crohns.2013.08.010. 2014
DNA methylation signatures associated with pathogenesis Crohn's disease-related genes
Tatay, IM; (...); Beltran, B
Meeting Abstract. 2019
Do antiTNF or Ustekinumab trough levels correlate with joint extraintestinal manifestations activity in Inflammatory bowel disease patients?
Madero Velazquez, L.; (...); Gutierrez Casbas, A.
Meeting Abstract. 2024
Do antiTNF through levels correlate with joint extraintestinal manifestations (EIM) activity in Inflammatory bowel disease (IBD) patients?
Madero Velazquez, L.; (...); Gutierrez Casbas, A.
Meeting Abstract. 2023
Early predictors of the need for surgery in patients with acute severe ulcerative colitis: results of the prospective, observational, international ESCP MASC study
Frasson, M.; (...); Pellino, G.
Meeting Abstract. 2023
Early treatment with anti-tumor necrosis factor agents improves long-term effectiveness in symptomatic stricturing Crohn's disease.
Rodríguez-Lago I; (...); Gisbert JP
Article. 10.1177/2050640620947579. 2020
Early Tuberculin Skin Test for the Diagnosis of Latent Tuberculosis Infection in Patients with Inflammatory Bowel Disease
Taxonera, C; (...); SEGURTB study gro GETECCU
Article. 10.1093/ecco-jcc/jjx022. 2017
Editorial: real-world short-term effectiveness of ustekinumab in 305 patients with Crohn's disease-results from the ENEIDA registry. Authors' reply
Editorial Material. 10.1111/apt.15447. 2019
Effect of the HLA-DQA1*05 allele on the efficacy of ustekinumab in patients with Crohn's Disease. Multicenter study based on the ENEIDA registry of GETECCU.
Guardiola Capon, J.; (...); Rodriguez-Moranta, F.
Meeting Abstract. 2024
Effectiveness and safety of a second-line rescue therapy for acute severe ulcerative colitis refractory to infliximab or ciclosporin (REASUC study)
Garcia, M. J.; (...); Chaparro, M.
Meeting Abstract. 2023
Effectiveness and safety of a third-line rescue treatment for acute severe ulcerative colitis refractory to infliximab or ciclosporin (REASUC study).
Garcia, Maria Jose; (...); Chaparro, Maria
Article. 10.1111/apt.17938. 2024
Effectiveness and safety of ustekinumab in ulcerative colitis: real-world evidence from Eneida Registry
Chaparro, M; (...); Esteve M
Meeting Abstract. 10.1093/ecco-jcc/jjz203.563. 2020
Effectiveness and safety of ustekinumab in ulcerative colitis: Real-world evidence from the ENEIDA registry.
Chaparro, Maria; (...); Lázaro Pérez-Calle, José
Article. 10.1093/ecco-jcc/jjab070. 2021
Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naive and non-naive patients
Iborra, M; (...); Spanish Working Group on Crohn’s Disease and Ulcerative Colitis (GETECCU).
Article. 10.1007/s00535-016-1274-1. 2017
Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naive and non-naive patients (vol 52, pg 788, 2017)
Iborra, M; (...); Spanish Working Group on Crohn’s Disease and Ulcerative Colitis (GETECCU).
Correction. 10.1007/s00535-016-1293-y. 2017
Effects of telemonitoring on safety and health care costs with a web platform (TECCU) in complex IBD patients: A randomised controlled trial
Meeting Abstract. 2018
Efficacy of Beclomethasone Dipropionate in Lowering Fecal Calprotectin Levels in Patients with Ulcerative Colitis in Clinical Remission and at Risk of Relapse: The Becalcu Randomized, Controlled Trial.
Ginard, Daniel; (...); Sans, Miquel
Article. 10.1159/000540792. 2024
Endoluminal radiofrequency ablation with SpyGlass in the management of cholangiocarcinoma.
Mansilla-Vivar R; (...); Pons-Beltrán V
Article. 10.17235/reed.2019.6230/2019. 2019
EpidemIBD: rationale and design of a large-scale epidemiological study of inflammatory bowel disease in Spain.
Chaparro M; (...); Gisbert JP
Article. 10.1177/1756284819847034. 2019
Epidemiology, clinical characteristics, evolution and treatments in newly diagnosed inflammatory bowel disease (IBD): results from the nationwide EpidemIBD study of GETECCU
Chaparro, M; (...); EpidemIBD Grp
Meeting Abstract. 10.1093/ecco-jcc/jjy222.914. 2019
Epidemiology, clinical characteristics, evolution and treatments in newly diagnosed inflammatory bowel disease (IBD): Results from the nationwide EpidemIBD study of GETECCU
Chaparro, M; (...); Gisbert, JP
Meeting Abstract. 2020
Epidemiology, diagnostic work-up and pharmacological requirements of inflammatory bowel disease (IBD) in Spain: Results from the nationwide EpidemIBD study of GETECCU
Chaparro, M; (...); EpidemIBD Grp
Meeting Abstract. 2018
Evaluation of tolerance to mercaptopurine in patients with inflammatory bowel disease and gastrointestinal intolerance to azathioprine.
Article. 10.1016/j.gastrohep.2023.12.001. 2024
Evolution of the emotional impact in patients with early inflammatory bowel disease during and after Covid-19 lockdown.
Sempere L; (...); Hofstadt CV
Article. 10.1016/j.gastrohep.2021.03.004. 2021
Extraintestinal Manifestations in Patients with Inflammatory Bowel Disease: Study Based on the ENEIDA Registry.
Algaba A; (...); Bermejo F
Article. 10.1007/s10620-020-06424-x. 2020
Faecal calprotectin and plasma cytokines in the prediction of early postoperative Crohn's disease recurrence
Cerrillo, E; (...); Beltran, B
Meeting Abstract. 2018
Faecal microbiota composition by shotgun metagenomic sequencing approach in a newly diagnosed cohort of inflammatory bowel disease patients: results from the IBDomics project.
Orejudo, M.; (...); Chaparro, M.
Meeting Abstract. 2024
Fecal Calprotectin in Ileal Crohn's Disease: Relationship with Magnetic Resonance Enterography and a Pathology Score
Cerrillo E; (...); Nos P
Article. 10.1097/MIB.0000000000000404. 2015
Fecal Calprotectin Pretreatment and Induction Infliximab Levels for Prediction of Primary Nonresponse to Infliximab Therapy in Crohn's Disease
Beltran, B; (...); Nos, P
Article. 10.1159/000492626. 2019
Fingolimod-induced remission in a patient with ulcerative colitis and multiple sclerosis.
Ladrón Abia P; (...); Bastida Paz G
Letter. 10.1016/j.gastrohep.2020.07.020. 2021
Gender Biases and Diagnostic Delay in Inflammatory Bowel Disease: Multicenter Observational Study.
Sempere L; (...); Ruiz-Cantero MT
Article. 10.1093/ibd/izad001. 2023
Genetic association between CD96 locus and immunogenicity to anti-TNF therapy in Crohn's disease.
Aterido, A; (...); Julia, A
Article. 10.1038/s41397-019-0090-4. 2019
Genetic Variants Associated with Biological Treatment Response in Inflammatory Bowel Disease: A Systematic Review.
Plaza J; (...); Moret-Tatay I
Article. 10.3390/ijms25073717. 2024
Hepatobiliary and Pancreatic: A fatal case of extensive splanchnic vein thrombosis in a patient with Covid-19.
Del Hoyo J; (...); Aguilera V
Editorial Material. 10.1111/jgh.15174. 2020
Identification of Epigenetic Methylation Signatures With Clinical Value in Crohn's Disease.
Moret-Tatay I; (...); Beltrán B
Article. 10.14309/ctg.0000000000000083. 2019
Identification of Risk Loci for Crohn's Disease Phenotypes Using a Genome-Wide Association Study
Alonso A; (...); Gisbert JP
Article. 10.1053/j.gastro.2014.12.030. 2015
Identification of serum and tissue micro-RNA expression profiles in different stages of inflammatory bowel disease.
Iborra M; (...); Danese S
Article. 10.1111/cei.12104. 2013
Identification of urine and serum diagnostic biomarkers of inflammatory bowel disease using a proteomic approach
Baldan-Martin, M.; (...); Chaparro, M.
Meeting Abstract. 2023
Idiopathic acute pancreatitis in patients with inflammatory bowel disease: A multicenter cohort study
de Paredes, AGG; (...); Lopez-Sanroman, A
Article. 10.1016/j.pan.2020.02.007. 2020
Ileal Predominance in Crohn's Disease Is Associated With Increased Intestinal Surgery and Biological Therapy Use, With Lower Treatment Persistence
Giordano, Antonio; (...); ENEIDA project of GETECCU
Article. 10.14309/ajg.0000000000003207. 2025
Immigrant IBD Patients in Spain Are Younger, Have More Extraintestinal Manifestations and Use More Biologics Than Native Patients.
Gutiérrez A; (...); Francés R
Article. 10.3389/fmed.2022.823900. 2022
Immunoepigenetic Regulation of Inflammatory Bowel Disease: Current Insights into Novel Epigenetic Modulations of the Systemic Immune Response.
Bastida, Guillermo; (...); Moret-Tatay, Ines
Article. 10.3390/genes14030554. 2023
Immunological Mechanisms of Adsorptive Cytapheresis in Inflammatory Bowel Disease
Saez-Gonzalez, Esteban; (...); Beltran, Belen
Review. 10.1007/s10620-017-4577-z. 2017
Impact of Anti-CD20 therapies on the immune homeostasis of gastrointestinal mucosa and their relationship with de novo intestinal bowel disease in multiple sclerosis: a review.
Quesada-Simo, A.; (...); Gil-Perotin, S.
Article. 10.3389/fphar.2023.1186016. 2023
Impact of comorbidities on anti-TNF alpha response and relapse in patients with inflammatory bowel disease: the VERNE study
Marin-Jimenez, I; (...); Barreiro-de Acosta, M
Article. 10.1136/bmjgast-2019-000351. 2020
Impact of co-morbidities on loss and lack of response to anti-TNFs in inflammatory bowel disease: VERNE study
Marin-Jimenez, I; (...); Barreiro-de Acosta, M
Meeting Abstract. 10.1093/ecco-jcc/jjy222.433. 2019
Impact of Smoking Cessation on the Clinical Course of Crohn's Disease Under Current Therapeutic Algorithms: A Multicenter Prospective Study
Nunes, T; (...); Sans, M
Article. 10.1038/ajg.2015.401. 2016
Impact of surveillance of hepatitis b and hepatitis c in patients with inflammatory bowel disease under anti-TNF therapies: Multicenter prospective observational study (REPENTINA 3)
Loras C; (...); Esteve M
Article. 10.1016/j.crohns.2014.06.009. 2014
Impact of telemonitoring on the management of Inflammatory Bowel Disease in Spain: a multicenter TECCU clinical trial
Peris, M. Aguas; (...); Nos, P.
Meeting Abstract. 2023
Impact of the European Society of Gastrointestinal Endoscopy 2020 guidelines on the number of scheduled post-polypectomy surveillance colonoscopies
Bustamante-Balen, Marco; (...); Pons-Beltran, Vicente
Article. 10.1055/a-1905-0155. 2022
Implementing telemedicine in inflammatory bowel disease: Is COVID-19 the definitive trigger?
Del Hoyo, J, Aguas, M
Editorial Material. 10.1016/j.gastrohep.2020.05.002. 2020
Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study
Chaparro, Maria; (...); Gisbert, Javier P.
Article. 10.3390/jcm10132885. 2021
Increased risk of thiopurine-related adverse events in elderly patients with IBD
Calafat, M; (...); ENEIDA Registry GETECCU
Article. 10.1111/apt.15458. 2019
INFLAMMATORY BOWEL DISEASE Diagnostic Performance of the Simple Clinical Colitis Activity Index Self-Administered Online at Home by Patients With Ulcerative Colitis: CRONICA-UC Study
Marin-Jimenez, I; (...); Panes, J
Article. 10.1038/ajg.2015.403. 2016
Inflammatory bowel disease integral care units: Evaluation of a nationwide quality certification programme. The GETECCU experience
Barreiro-de Acosta, M; (...); Nos, P
Article. 10.1002/ueg2.12105. 2021
Inflammatory Bowel Disease Unclassified and Ulcerative Colitis: different outcomes? Multicenter case-control study (Spanish ENEIDA registry)
Gonzalez Vivo, M.; (...); Marquez, L.
Meeting Abstract. 2022
Infliximab Dose Escalation as an Effective Strategy for Managing Secondary Loss of Response in Ulcerative Colitis
Taxonera C; (...); Fernández-Blanco I
Article. 10.1007/s10620-015-3735-4. 2015
Influence of concomitant immunomodulators during maintenance therapy with Adalimumab in inflammatory bowel disease: looking for the ideal patient to use monotherapy
Bastida, G; (...); Nos, P
Meeting Abstract. 10.1093/ecco-jcc/jjy222.581. 2019
Influence of familial forms of inflammatory bowel disease on the use of immunosuppressants, biological agents, and surgery in the era of biological therapies. Results from the ENEIDA project.
Gonzalez-Munoza, Carlos; (...); Domenech, Eugeni
Article. 10.1093/postmj/qgae076. 2024
Influence of Vitamin D Deficiency on Inflammatory Markers and Clinical Disease Activity in IBD Patients
Lopez-Munoz, P; (...); Iborra, M
Article. 10.3390/nu11051059. 2019
Information resources used by patients with inflammatory bowel disease: Satisfaction, expectations and information gaps
Catalán-Serra I; (...); Hinojosa J
Article. 10.1016/j.gastrohep.2014.09.003. 2015
Irritable Bowel Syndrome in Inflammatory Bowel Disease. Synergy in alterations of the gut-brain axis?
Pérez de Arce E; (...); Nos P
Article. 10.1016/j.gastrohep.2021.02.022. 2021
Is the switch to a second thiopurine a safe strategy in elderly patients with inflammatory bowel disease? A multi-centre cohort study of the ENEIDA registry
Calafat, M; (...); ENEIDA Registry GETECCU
Meeting Abstract. 10.1093/ecco-jcc/jjy222.548. 2019
Is the withdrawal of anti-tumour necrosis factor in inflammatory bowel disease patients in remission feasible without increasing the risk of relapse? Results from the randomised clinical trial of GETECCU (EXIT)
Chaparro, M.; (...); Gisbert, J. P.
Meeting Abstract. 2023
Knotting of Duodopa (R) duodenal infusion system
del-Hoyo-Francisco J; (...); Pons-Beltrán V
Letter. 2015
Leishmania infection in patients with inflammatory bowel disease: Case series and literature review.
Gimeno-Pitarch L, Almela P, Nos P
Article. 10.1016/j.gastrohep.2023.04.001. 2024
Letter: management of post-operative Crohn's disease - thiopurines vs adalimumab
Letter. 10.1111/apt.13433. 2016
Long-Term Efficacy and Safety of Cyclosporine in a Cohort of Steroid-Refractory Acute Severe Ulcerative Colitis Patients from the ENEIDA Registry (1989-2013): A Nationwide Multicenter Study
Ordás I; (...); Esteve M
Article. 10.1038/ajg.2017.180. 2017
Long-term impact of early medical prevention of postoperative recurrence on second intestinal resections in patients with Crohn's Disease. Data from the ENEIDA registry
Pinero, G. S.; (...); Domenech, E.
Meeting Abstract. 10.1093/ecco-jcc/jjae190.0794. 2025
Long-term outcome of ulcerative colitis patients responders to cyclosporine in the biological era
Bastida, G; (...); Lobaton, T
Meeting Abstract. 2017
Long-term outcomes of newly diagnosed Inflammatory Bowel Disease (IBD) patients: results from the nationwide EpidemIBD study of GETECCU
Chaparro, M.; (...); Gisbert, J. P.
Meeting Abstract. 2024
Long-term safety and efficacy of budesonide in the treatment of ulcerative colitis.
Iborra M, Alvarez-Sotomayor D, Nos P
Article. 10.2147/CEG.S34715. 2014
Long-Term Safety of In Utero Exposure to Anti-TNF alpha Drugs for the Treatment of Inflammatory Bowel Disease: Results from the Multicenter European TEDDY Study
Chaparro, M; (...); Gisbert, JP
Article. 10.1038/ajg.2017.501. 2018
Management of acute severe ulcerative colitis in Spain: A nationwide clinical practice survey
Rodriguez-Lago, I; (...); Gisbert, JP
Article. 10.1016/j.gastrohep.2018.09.002. 2019
Management of immunomodulators and biologic agents in pregnant patients with inflammatory bowel: results from the DUMBO registry of GETECCU
Chaparro, M.; (...); Gisbert, J. P.
Meeting Abstract. 2022
Metagenomic Analysis of Crohn's Disease Patients Identifies Changes in the Virome and Microbiome Related to Disease Status and Therapy, and Detects Potential Interactions and Biomarkers
Pérez-Brocal V; (...); Moya A
Article. 10.1097/MIB.0000000000000549. 2015
MicroRNA and granulocyte-monocyte adsorption apheresis combotherapy after inadequate response to anti-TNF agents in ulcerative colitis.
Saez-Gonzalez, Esteban; (...); Beltran, Belen
Article. 10.1002/jca.22101. 2023
Multicriteria Decision Analysis for Updating of Quality Indicators for Inflammatory Bowel Disease Comprehensive Care Units in Spain.
Calvet X; (...); Barreiro-de Acosta M
Article. 10.1093/ecco-jcc/jjac068. 2022
Need for therapeutic escalation in patients with refractory ulcerative proctitis: Results from the PROCU study of the ENEIDA registry.
Ferreiro-Iglesias, Rocio; (...); Barreiro-de Acosta, Manuel
Article. 10.1111/apt.18133. 2024
Noninvasive Testing for Mucosal Inflammation in Inflammatory Bowel Disease.
Article. 10.1016/j.giec.2016.06.005. 2016
Novel biomarkers associated with inflammatory bowel disease
Baldan-Martin, M.; (...); Chaparro, M.
Meeting Abstract. 2024
Observational study on the efficacy of adalimumab for the treatment of ulcerative colitis and predictors of outcome.
García-Bosch O; (...); Panés J
Article. 10.1016/j.crohns.2012.10.004. 2013
Optimization through iv maintenance with ustekinumab in Inflammatory Bowel Disease. Efficacy and adjusted regimen in real world
Minguez, A.; (...); Bastida, G.
Meeting Abstract. 2024
Optimizing outcomes with maintenance IV UST in highly bio-exposed patients with IBD. Efficacy and adjusted regimen in real world.
Minguez, Alejandro; (...); Bastida, Guillermo
Article. 10.1016/j.gastrohep.2024.502253. 2024
Outcomes of Medical and Surgical Therapy for Entero-urinary Fistulas in Crohn's Disease
Taxonera, C; (...); Fernandez-Blanco, I
Article. 10.1093/ecco-jcc/jjw016. 2016
Oxidative Stress in the Pathogenesis of Crohn's Disease and the Interconnection with Immunological Response, Microbiota, External Environmental Factors, and Epigenetics
Alemany-Cosme, E; (...); Beltran, B
Review. 10.3390/antiox10010064. 2021
Performance of Screening Strategies for Latent Tuberculosis Infection in Patients with Inflammatory Bowel Disease: Results from the ENEIDA Registry of GETECCU.
Riestra S; (...); Domènech E
Article. 10.3390/jcm11133915. 2022
Periesophageal Lymph Node Metastasis of Prostate Adenocarcinoma From Liver Transplant Donor
Sanchez-Montes, C; (...); Arguello, L
Editorial Material. 10.14309/ajg.0000000000000135. 2019
Persistence, effectiveness and safety of ustekinumab and vedolizumab therapy for complex perianal fistula in Crohn's disease: The HEAL study from GETECCU.
Casanova, Maria Jose; (...); Gisbert, Javier P
Article. 10.1016/j.dld.2024.05.009. 2024
Personalised therapy in inflammatory bowel disease
Calderón P; (...); Quera R
Article. 10.1016/j.gastrohep.2023.12.006. 2024
Phenotype and natural history of elderly onset inflammatory bowel disease: a multicentre, case-control study
Manosa, M; (...); Geteccu
Article. 10.1111/apt.14494. 2018
Phenotypic concordance in familial inflammatory bowel disease (IBD). Results of a nationwide IBD Spanish database
Cabré E; (...); Domènech E
Article. 10.1016/j.crohns.2013.12.005. 2014
Phenotypic characteristics and use of therapeutic resources in elderly-onset inflammatory bowel disease: A multicentre, case control study
Manosa, M.; (...); Domenech, E.
Article. 10.1016/S1873-9946(14)60726-1. 2014
Plasma Oncostatin M, TNF-a, IL-7, and IL-13 Network Predicts Crohn's Disease Response to Infliximab, as Assessed by Calprotectin Log Drop.
Mateos B; (...); Beltrán B
Article. 10.1159/000508069. 2020
Position statement of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis on sexuality and inflammatory bowel disease.
Calvo Moya M; (...); Gutiérrez Casbas A
Article. 10.1016/j.gastrohep.2023.12.013. 2024
Possible Biomarkers in Blood for Crohn's Disease: Oxidative Stress and MicroRNAs-Current Evidences and Further Aspects to Unravel
Moret-Tatay I; (...); Beltrán B
Review. 10.1155/2016/2325162. 2016
Possible role of chondroitin sulphate and glucosamine for primary prevention of colorectal cancer. Results from the MCC-Spain study
Ibanez-Sanz, Gemma; (...); Moreno, Victor
Article. 10.1038/s41598-018-20349-6. 2018
Prevalence and factors associated with Inflammatory Bowel Disease (IBD) activity during pregnancy: updated data from the DUMBO Registry
Chaparro, M.; (...); Gisbert, J. P.
Meeting Abstract. 2024
Prevention of postoperative recurrence of Crohn's disease with vedolizumab: First results of the prospective placebo-controlled randomised trial REPREVIO
D'Haens, G.; (...); Laharie, D.
Meeting Abstract. 2023
Primary prevention of post-operative recurrence of Crohn's disease with anti-TNF agents in real life. Preliminary data from the Spanish ENEIDA registry
Canete, F; (...); Domenech, E
Meeting Abstract. 2018
Proteomic characterization of serum extracellular vesicles from newly diagnosed patients with inflammatory bowel disease
Soleto, I.; (...); Chaparro, M.
Meeting Abstract. 2023
Proteomic profile of serum and urine in newly diagnosed patients with Inflammatory Bowel Disease: new approach for biomarker discovery
Baldan-Martin, M.; (...); Gisbert, J. P.
Meeting Abstract. 2022
Psoriasis induced by antiTNF therapy in inflammatory bowel disease: Therapeutic management and evolution of both diseases in a nationwide cohort study.
Sanz Segura, Patricia; (...); Garcia-Lopez, Santiago
Article. 10.1016/j.dld.2024.05.021. 2024
Psychological burden and quality of life in newly diagnosed inflammatory bowel disease patients.
Bernabeu P; (...); Sempere L
Article. 10.3389/fpsyg.2024.1334308. 2024
Psychological burden in newly diagnosed IBD patients: Differences between Crohn's Disease and Ulcerative Colitis in early IBD
Bernabeu, P.; (...); Sempere, L.
Article. 2022
Psychosocial impact of the COVID-19 pandemic on patients with inflammatory bowel disease in Spain
Hernandez Camba, A.; (...); Barreiro, M.
Meeting Abstract. 10.1093/ecco-jcc/jjab076.312. 2021
Psychosocial impact of the COVID-19 pandemic on patients with inflammatory bowel disease in Spain. A post lockdown reflection.
Hernandez Camba, Alejandro; (...); Barreiro-de Acosta, Manuel
Article. 10.1016/j.gastrohep.2021.08.007. 2021
Quality of life during one year of postoperative prophylactic drug therapy after intestinal resection in Crohn's patients: Results of the APPRECIA trial
Taxonera, C; (...); Nos, P
Article. 10.1016/j.dld.2019.01.002. 2019
Randomized controlled trial on the effect of megaboluses of intravenous corticosteroids added to oral corticosteroids in the treatment of moderately active ulcerative colitis
Llao, J.; (...); Moral, E. Domenech
Meeting Abstract. 2023
Rate of adverse events of gastroduodenal snare polypectomy for non-flat polyp is low: A prospective and multicenter study
Cordova, H; (...); Fernandez-Esparrach, G
Article. 10.3748/wjg.v23.i47.8405. 2017
Real life 2 year experience with ustekinumab in a Spanish open-label cohort of ulcerative colitis patients.
Iborra Colomino, M. I.; (...); Nos, P.
Meeting Abstract. 2023
Real life effectiveness of Adalimumab for the treatment of ulcerative colitis: comparison between anti-TNF-naive and non-naive patients. Results from the Spanish ENEIDA Registry.
Iborra, M.; (...); Nos, P.
Meeting Abstract. 2015
Real-life experience with 4 years of golimumab persistence in ulcerative colitis patients.
Article. 10.1038/s41598-020-73577-0. 2020
Real-life experience with long-term maintenance of golimumab in ulcerative colitis patients
Meeting Abstract. 10.1093/ecco-jcc/jjy222.683. 2019
Real-world data on the infliximab biosimilar CT-P13 (Remsima(®)) in inflammatory bowel disease.
Huguet, JM; (...); Paredes, JM
Article. 10.12998/wjcc.v9.i36.11285. 2021
Real-world effectiveness of vedolizumab in managing refractory pouchitis: a multicenter study on intravenous to subcutaneous transition
Gimeno-Pitarch, L.; (...); Iborra, M.
Meeting Abstract. 10.1093/ecco-jcc/jjae190.1018. 2025
Real-world long-term effectiveness of ustekinumab in Crohn's disease: results from the ENEIDA registry
Article. 10.1111/apt.15958. 2020
Real-world long-term effectiveness of ustekinumab in Crohn's disease: Results from the ENEIDA registry
Iborra Colomino, M. I.; (...); Nos, P.
Meeting Abstract. 2020
Real-world long-term effectiveness of ustekinumab in ulcerative colitis: results from a spanish open-label cohort.
Iborra, Marisa; (...); Nos, Pilar
Article. 10.1080/00365521.2023.2278427. 2023
Real-world short and long-term effectiveness of risankizumab in refractory Crohn's disease: RISANCROHN study from the ENEIDA Registry
Barreiro-de Acosta, M.; (...); Ferreiro-Iglesias, R.
Meeting Abstract. 10.1093/ecco-jcc/jjae190.0783. 2025
Real-world short-term effectiveness of ustekinumab in 305 patients with Crohn's disease: results from the ENEIDA registry
Iborra, M; (...); Chaparro, M
Article. 10.1111/apt.15371. 2019
Real-world short-term effectiveness of ustekinumab in Crohn's disease: Results from the ENEIDA Registry
Meeting Abstract. 10.1093/ecco-jcc/jjy222.629. 2019
Recommendations by the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the treatment of patients with inflammatory bowel disease associated with spondyloarthritis
Gonzalez-Lama, Y; (...); Gomollon, F
Article. 10.1016/j.gastrohep.2020.01.005. 2020
Recommendations of the Crohn's Disease and Ulcerative Colitis Spanish Working Group (GETECCU) for the treatment of perianal fistulas of Crohn's disease.
Boscá MM; (...); Hinojosa J
Review. 10.1016/j.gastrohep.2019.09.012. 2020
Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on pouchitis in ulcerative colitis. Part 1: Epidemiology, diagnosis and prognosis.
Barreiro-de Acosta M; (...); Nos P
Editorial Material. 10.1016/j.gastrohep.2019.08.001. 2019
Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on pouchitis in ulcerative colitis. Part 2: Treatment.
Barreiro-de Acosta M; (...); Nos P
Article. 10.1016/j.gastrohep.2020.04.004. 2020
Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the monitoring, prevention and treatment of post-operative recurrence in Crohn's disease
Domènech E; (...); Mañosa M
Review. 10.1016/j.gastrohep.2017.05.005. 2017
Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the use of tiopurines in inflammatory bowel disease
Berrnejo, F; (...); Lopez-Sanroman, A
Review. 10.1016/j.gastrohep.2017.11.007. 2018
Recommendations of the Valencian Society of Digestive Pathology for the use of telemedicine and non-contact consultations.
Jover, Rodrigo; (...); Nos, Pilar
Article. 10.1016/j.gastrohep.2021.04.009. 2022
Regression of a giant pseudopolyp in a patient with colonic Crohn's disease after therapy with infliximab.
Sánchez Melgarejo JF; (...); Nos P
Article. 10.17235/reed.2019.6252/2019. 2019
Re-induction With Intravenous Ustekinumab in Patients With Crohn's Disease and a Loss of Response to This Therapy.
Bermejo F; (...); Guerra I
Article. 10.1093/ibd/izab015. 2021
Relevance of Clinical Cases.
Balaguer, Francesc; (...); Saez Gonzalez, Esteban
Editorial Material. 10.1016/j.gastrohep.2022.02.001. 2022
Relevance of dynamic studies with magnetic resonance enterography in Crohn's disease.
Pous S; (...); Nos P
Article. 10.1016/j.gastrohep.2019.11.010. 2020
Review of computational methods for the detection and classification of polyps in colonoscopy imaging
Sánchez-Montes C; (...); Fernández-Esparrach G
Review. 10.1016/j.gastrohep.2019.11.004. 2020
Reviewing the therapeutic role of budesonide in Crohn's disease
Lopez-Sanroman, A; (...); Domenech, E
Review. 10.1016/j.gastrohep.2018.05.013. 2018
Risk of immunomediated adverse events and loss of response to infliximab in elderly patients with inflammatory bowel disease. A cohort study of the ENEIDA registry.
Calafat M; (...); ENEIDA Study Group of GETECCU
Article. 10.1093/ecco-jcc/jjab213. 2021
Risk of immunomediated adverse events or secondary loss of response to infliximab in elderly patients with inflammatory bowel disease: a cohort study of the ENEIDA registry
Calafat, M; (...); Domenech, E
Meeting Abstract. 10.1093/ecco-jcc/jjy222.561. 2019
Role of Interleukin-8 in Predicting Long-Term Response to Vedolizumab in Ulcerative Colitis Patients
Minguez, A.; (...); Nos, P.
Meeting Abstract. 10.1093/ecco-jcc/jjae190.1111. 2025
Safety of live vaccines in children exposed to biological agents for inflammatory bowel disease (IBD) in utero or during breastfeeding
Chaparro, M.; (...); Gisbert, J. P.
Meeting Abstract. 2023
Safety of ustekinumab in pregnant patients with inflammatory bowel disease and in their offspring: results from the DUMBO registry of GETECCU
Chaparro, M.; (...); Gisbert, J. P.
Meeting Abstract. 2022
Secondary Haemophagocytic Syndrome and Overlapping Immune Reconstitution Syndrome: Life-Threatening Complications of Anti-TNF-alpha Treatment for Crohn's Disease
Saez-Gonzalez, E; (...); Beltran, B
Letter. 10.1038/s41395-018-0420-1. 2019
Secukinumab-induced ulcerative colitis: opening Pandora's box of immunity
Fernandez-de La Varg, M; (...); Paz, GB
Letter. 10.1016/j.gastrohep.2019.12.004. 2020
Serial Tuberculin Skin Tests Improve the Detection of Latent Tuberculosis Infection in Patients With Inflammatory Bowel Disease
Taxonera, C; (...); CONVERT Study Grp GETECCU
Article. 10.1093/ecco-jcc/jjy104. 2018
Serum Adalimumab Levels Predict Successful Remission and Safe Deintensification in Inflammatory Bowel Disease Patients in Clinical Practice
Aguas Peris M; (...); Nos, P
Article. 10.1097/MIB.0000000000001182. 2017
Serum adalimumab levels predict successful remission and safe de-intensification in inflammatory bowel disease patients in clinical practice
Meeting Abstract. 2017
Serum and Urine Metabolomic Profiling of Newly Diagnosed Treatment-Naive Inflammatory Bowel Disease Patients
Aldars-Garcia, Laila; (...); Chaparro, Maria
Article. 10.1093/ibd/izad154. 2024
Short-term real-world effectiveness and safety of granulocyte and monocyte adsorptive apheresis (GMA) in patients with inflammatory bowel disease: GRACE Study
Rodriguez-Lago, I.; (...); Cabriada, J. L.
Meeting Abstract. 2024
Should professionals provide their patients with digital health training resources?
Piudo, AE; (...); Marcos, NM
Meeting Abstract. 2020
Skin injuries associated with biological therapy in inflammatory bowel disease: beyond psoriasis.
Mínguez Sabater A; (...); Bastida G
Article. 10.1016/j.gastrohep.2020.09.003. 2022
Small intestinal bacterial overgrowth in inactive Crohn's disease: Influence of thiopurine and biological treatment
Sánchez-Montes C; (...); Nos P
Article. 10.3748/wjg.v20.i38.13999. 2014
Smoking does influence disease behaviour and impacts the need for therapy in Crohn's disease in the biologic era.
Nunes T; (...); Panés J
Article. 10.1111/apt.12440. 2013
Specific plasma micro-RNA profiles for prediction of recurrence in Crohn's disease in pre-surgery and established recurrence scenarios
Moret, I; (...); Beltran, B
Meeting Abstract. 2020
Specific Plasma MicroRNA Signatures in Predicting and Confirming Crohn's Disease Recurrence: Role and Pathogenic Implications.
Moret-Tatay, Ines; (...); Beltran, Belen
Article. 10.14309/ctg.0000000000000416. 2021
Stopping azathioprine in monotherapy after very prolonged remission in inflammatory bowel disease patients: Novel relapse risk factors
Meeting Abstract. 2018
Subcutaneous infliximab cut-off points in a large cohort of Spanish patients with inflammatory bowel disease and factors associated with long-term outcomes
Iborra, M.; (...); Nos, P.
Meeting Abstract. 2024
Subcutaneous infliximab cut-off points in patients with inflammatory bowel disease. Data from the ENEIDA registry.
Article. 10.1093/ecco-jcc/jjae127. 2024
Sucrosomial Iron Supplementation for the Treatment of Iron Deficiency Anemia in Inflammatory Bowel Disease Patients Refractory to Oral Iron Treatment.
Article. 10.3390/nu13061770. 2021
Surgery due to inflammatory bowel disease during pregnancy: mothers and offspring outcomes (SCAR Study)
Chaparro, M.; (...); ECCO CONFER Taskforce
Meeting Abstract. 2022
Surgery due to Inflammatory Bowel Disease During Pregnancy: Mothers and Offspring Outcomes From an ECCO Confer Multicentre Case Series [Scar Study]
Chaparro, Maria; (...); Julsgaard, Mette
Article. 10.1093/ecco-jcc/jjac050. 2022
Surgical and hospital admission in adults newly diagnosed with inflammatory bowel disease (IBD) in the biological era in Spain: Results of the nationwide EpidemIBD study of GETECCU
Chaparro, M; (...); EpidemIBD Group
Meeting Abstract. 2018
Survey of adherence to treatment in inflammatory bowel disease. ENADEII study.
Alonso-Abreu I; (...); Quintero-Carrión E
Article. 10.1016/j.gastrohep.2019.10.007. 2020
Survey of adherence to treatment in inflammatory bowel disease: ENADEII STUDY
Abreu, IA; (...); GETECCU
Meeting Abstract. 2019
Switching to a Second Thiopurine in Adult and Elderly Patients With Inflammatory Bowel Disease: A Nationwide Study From the ENEIDA Registry.
Calafat M; (...); Domènech E
Article. 10.1093/ecco-jcc/jjaa055. 2020
Switching to standard-dose subcutaneous vedolizumab increases the percentage of patients in biochemical remission even in those intensified with intravenous vedolizumab: one year results of a Spanish multicentre observational study
Andres Pascual, L.; (...); Sicilia, B.
Meeting Abstract. 10.1093/ecco-jcc/jjae190.1000. 2025
Takayasu's arteritis associated with Crohn's disease.
Tung Chen Y; (...); Nos Mateu P
Article. 10.1016/j.rce.2014.01.012. 2014
Telemedicine in Inflammatory Bowel Disease: Opportunities and Approaches
Aguas Peris M; (...); Nos P
Article. 10.1097/MIB.0000000000000241. 2015
Telemedicine in Inflammatory Bowel Disease: Opportunity Ahead
Letter. 10.1097/MIB.00000000000676. 2016
Telemedicine in the treatment of patients with inflammatory bowel disease
Review. 10.1016/j.gastrohep.2017.07.001. 2017
Telemonitoring of Crohn's Disease and Ulcerative Colitis (TECCU): Cost-Effectiveness Analysis.
Del Hoyo J; (...); Aguas M
Article. 10.2196/15505. 2019
Telemonitoring with TECCU of active Inflammatory Bowel Disease is Not Inferior to Standard Care: Short-term Results of a Multicentre Randomized Controlled Trial of GETECCU.
Article. 10.2196/60966. 2024
The availability of anti-TNF agents is associated with reduced early surgical requirements in Crohn's disease but not in ulcerative colitis. A nationwide study from the Eneida registry
Guasch, M; (...); Domenech, E
Meeting Abstract. 2018
The characteristics of the stricture, but not the ongoing treatment, could influence the outcome of endoscopic dilation in recurrent Crohn's disease.
Ladron Abia, Pablo; (...); Iborra, Marisa
Article. 10.1016/j.gastrohep.2022.01.004. 2022
The ENEIDA registry (Nationwide study on genetic and environmental determinants of inflammatory bowel disease) by GETECCU: Design, monitoring and functions.
Zabana Y; (...); Domènech E
Article. 10.1016/j.gastrohep.2020.05.007. 2020
The Harvey-Bradshaw Index Adapted to a Mobile Application Compared with In-Clinic Assessment: The MediCrohn Study.
Echarri A; (...); Muñiz J
Article. 10.1089/tmj.2018.0264. 2020
The initiation of thiopurines in elderly patients with inflammatory bowel disease is associated with an increased risk of adverse effects: a case-control study of the ENEIDA registry
Calafat, M; (...); Domenech, E
Meeting Abstract. 2018
The Risk of Developing Disabling Crohn's Disease: Validation of a Clinical Prediction Rule to Improve Treatment Decision Making
Bastida Paz, Guillermo; (...); Nos, Pilar
Article. 10.1159/000531789. 2023
Therapeutic drug monitoring during induction therapy with Ustekinumab in patients with Crohn's disease: the key to early identification of patients with inadequate response
Minguez, A.; (...); Nos, P.
Meeting Abstract. 2023
Tofacitinib in Ulcerative Colitis: Real-world Evidence From the ENEIDA Registry.
Chaparro M; (...); Gisbert JP
Article. 10.1093/ecco-jcc/jjaa145. 2021
Treatment patterns and intensification within 5 year of follow-up of the first-line anti-TNFalpha used for the treatment of IBD: Results from the VERNE study.
Bastida G; (...); Barreiro-de Acosta M
Article. 10.1016/j.dld.2021.06.005. 2021
Types, behaviour and therapeutic requirements of inflammatory pouch disorders: Results from the RESERVO study of GETECCU.
Mesonero F; (...); Barreiro-de Acosta M
Article. 10.1016/j.dld.2024.09.023. 2024
Undetectable levels of adalimumab in clinical practice: Should we say goodbye to the drug?
Bejar, S; (...); Mateu, PN
Meeting Abstract. 2020
Urine metabolome profiling of immune-mediated inflammatory diseases
Alonso, A; (...); IMID Consortium
Article. 10.1186/s12916-016-0681-8. 2016
Use of Magnetic Resonance Index of Activity (MaRIA) in the preoperative assessment of small bowel Crohn's disease.
Pous-Serrano, S; (...); Garcia-Granero, E
Article. 10.1016/j.ciresp.2019.06.018. 2019
Use of telemedicine in inflammatory bowel disease: a real monitoring option?
Editorial Material. 10.1080/17474124.2016.1200464. 2016
Ustekinumab and vedolizumab as first-line biological therapy for inflammatory bowel disease. A multicenter study based on the ENEIDA registry.
Sard, M. Calafat; (...); Domenech, E.
Meeting Abstract. 2023
Ustekinumab and vedolizumab for the prevention of postoperative recurrence of Crohn's disease: Results from the ENEIDA registry.
Manosa, Miriam; (...); Domenech, Eugeni
Article. 10.1016/j.dld.2022.07.013. 2022
Ustekinumab as an opportunity for refractory Ulcerative Colitis patients
Iborra, M.; (...); Nos, P.
Meeting Abstract. 2022
Ustekinumab for the Treatment of Refractory Crohn's Disease: The Spanish Experience in a Large Multicentre Open-label Cohort
Khorrami, S; (...); Gisbert, JP
Article. 10.1097/MIB.0000000000000842. 2016
Ustekinumab levels correlate with induction fecal calprotectin drop-slope and discriminate the need for intensification at week 52 in Crohn's Disease patients
Mateos, B.; (...); Beltran, B.
Meeting Abstract. 10.1093/ecco-jcc/jjab076.697. 2021
Variability in Mesalazine Management for Ulcerative Proctitis Include Doses, Route of Administration and Use of Fecal Calprotectin: Insights from Clinical Practice Across Spain Beyond Clinical Guidelines
Bastida Paz, G.; (...); Gonzalez-Lama, Y.
Meeting Abstract. 2024
Vedolizumab to prevent postoperative recurrence of Crohn's disease (REPREVIO): a multicentre, double-blind, randomised, placebo-controlled trial.
D'Haens, Geert; (...); Laharie, David
Article. 10.1016/S2468-1253(24)00317-0. 2025
Vedolizumab, an adequate option in medically refractory and thiopurine-intolerant inflammatory bowel disease patients
Meeting Abstract. 2018
Vedolizumab, an option in patients with inflammatory bowel disease intolerant to thiopurines and refractory to biological agents
Article. 10.1016/j.gastrohep.2018.06.001. 2018
Withdrawal of Azathioprine in Inflammatory Bowel Disease Patients Who Sustain Remission: New Risk Factors for Relapse
Article. 10.1007/s10620-018-5429-1. 2019